Opsona Therapeutics, founded in 2004, is a pioneering drug development company specializing in the human immune system. The company's primary focus lies in identifying innovative approaches to prevent and treat autoimmune/inflammatory conditions, cancers, and infectious diseases. Opsona's drug discovery & development is centered around the role of Toll-Like Receptors (TLRs) and Inflammasome signaling in human immunology. Notably, since 2004, Opsona has established a unique and advanced pipeline of drugs, with research locations in Dublin (Ireland) and Lausanne (Switzerland). In October 2013, Opsona Therapeutics secured a significant investment of €3.00M in a Series C funding round. The round witnessed participation from a consortium of prominent investors including Amgen Ventures, Novartis Venture Fund, Omnes Capital, Sunstone Capital, Enterprise Ireland, BB Biotech Ventures, EMBL Ventures, Fountain Healthcare Partners, Roche Venture Fund, and Baxter International. This impressive list of investors speaks to the confidence and support the company has garnered within the biotechnology and healthcare industries. Opsona's innovative approach and the backing of established investors position the company as a compelling player in the biopharmaceutical landscape.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series C | €3.00M | 10 |
|
02 Oct 2013 |
| Series C | €33.00M | - | 29 Apr 2013 | |
| Series B | $4.60M | - | 16 Jun 2009 | |
| Series B | €18.00M | - | 19 Feb 2009 | |
| Series A | $6.60M | - | 24 Feb 2005 |
No recent news or press coverage available for Opsona Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
